Non-Steroidal Anti-Inflammatory Drug-Induced Enteropathy.
- Author:
Yun Jeong LIM
1
;
Chang Hun YANG
Author Information
- Publication Type:Review ; Clinical Trial
- Keywords: Anti-inflammatory agents, non-steroidal; Lower gastrointestinal tract; Cyclooxygenase 2 inhibitors
- MeSH: Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Cyclooxygenase 2 Inhibitors; Humans; Incidence; Lower Gastrointestinal Tract
- From:Clinical Endoscopy 2012;45(2):138-144
- CountryRepublic of Korea
- Language:English
- Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed drugs in the world. NSAID-induced lower gastrointestinal (GI) complications are increasing while upper GI complications are decreasing. Lower GI events accounted for 40% of all serious GI events in patients on NSAIDs. Capsule endoscopy and device assisted enteroscopy are available for detection of small intestinal lesions. Capsule endoscopy studies have demonstrated that NSAIDs use in healthy volunteers raised the incidence (55% to 75%) of intestinal damage. It appears that selective cyclooxygenase-2 inhibitors (coxibs) improved upper and lower GI safety based on results of clinical trials. Selective coxibs are still capable of triggering GI adverse events and cardiovascular toxicity issues were the main focus of concerns. Unfortunately, definite strategies are not available to prevent or heal NSAID-induced intestinal injuries. Thus, there is still a strong clinical need for effective drugs with improved safety profiles than the existing NSAIDs.
